Blog Category

News

08
Apr 2021

Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
08
Mar 2021

BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020

BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
11
Feb 2021

BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial

A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
27
Jan 2021

BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target

BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.